Licata & Tyrrell P.C.
Compositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance
The present invention relates to methods for enhancing the cellular uptake and clearance of soluble oligomeric Aβ peptide assemblies from the environment surrounding both neuronal and non-neuronal cells. Oligomeric Aβ peptide assembly uptake and clearance is achieved via an agent that enhances insulin receptor signaling. Such ADDL uptake enhancers represent effective anti-ADDL therapeutics for use in the therapeutic treatment and/or prophylactic treatment of diseases including Alzheimer's disease, Down's syndrome, and the like, in which compromised nerve cell function is linked to the formation and/or the activity of soluble oligomeric Aβ peptide assemblies, also known as ADDLs, and ADDL-related assemblies.
Northwestern University Acumen Pharmaceuticals, Inc.
G G G A
G01N G01N G01N A61K
additional inventional inventional inventional
Wei-Qin Grant A. William L.
Zhao Krafft Klein